Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

LONDON - GSK plc (LSE/NYSE: LON:GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic ...

THURSDAY, Feb. 6, 2025 (HealthDay News) -- A few baseline characteristics can predict the need for recurrent endoscopic sinus ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Kaivan Khavandi, SVP at GSK, stated, "Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma and CRSwNP for ...